✅Development: It is Developed with support from the Biotechnology Industry Research Assistance Council (BIRAC) and brought to market by Wockhardt under the name Miqnaf.
🔸The development of Nafithromycin took 14 years of research and an investment of ₹500 crore, with clinical trials conducted in the U.S., Europe, and India.
✅It is designed to treat Community-Acquired Bacterial Pneumonia (CABP) caused by drug-resistant bacteria, particularly affecting vulnerable groups like children, the elderly, and immune-compromised patients.
✅Effectiveness : The antibiotic is ten times more effective than azithromycin, with a three-day treatment regimen that is safer, faster, and better tolerated by patients.
🔸It has minimal side effects and no significant drug interactions, making it a versatile solution.
Social